Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomasGrenader, Tala; Goldberg, Anthonya; Hadas-Halperin, Iritb; Gabizon, AlbertoaAnti-Cancer Drugs: January 2009 - Volume 20 - Issue 1 - p 15-20 doi: 10.1097/CAD.0b013e3283198058 PRECLINICAL REPORTS Buy Abstract Author InformationAuthors Article MetricsMetrics Doxorubicin and ifosfamide are currently considered the cornerstones of treatment for advanced soft tissue sarcomas (STSs). Pegylated liposomal doxorubicin (PLD) has been shown to have equivalent activity to doxorubicin and an improved toxicity profile. A review of the medical records of 11 patients with a variety of STSs treated with PLD was performed. The median age of the patients was 54.8 years. Of the 11 patients, seven received no earlier systemic therapy for their sarcoma. The initial dose per course was 40–60 mg/m2 every 4 weeks with dose reduction to 40 mg/m2 in the second or third cycle. A median of 11 cycles was given (range, two to 29 cycles). Treatment was generally well tolerated. We did observe some toxic effects as described earlier with PLD, including mild myelosuppression, skin toxicity and fatigue. No cardiotoxicity was observed. Of the 11 treated patients, six had a partial response, two had a best response of stable disease and three had progressive disease. All six patients with a partial response had an extended time to progression. To date, two patients continue on treatment (15 and seven cycles); one patient has stable disease 60 months after withdrawal of PLD (after eight cycles) and one patient had progression of disease 7 months after the withdrawal of therapy after 20 cycles. Of the two patients with stabilization of their disease, one had progression after 29 months and one continues on treatment for 6 months. PLD is active and safe for long-term treatment of metastatic STSs and may be important in maintaining response. Departments of aOncology bDiagnostic Radiology, Shaare Zedek Medical Center, Jerusalem, Israel Correspondence to Dr Tal Grenader, Department of Oncology, Shaare Zedek Medical Center, PO Box 3235, Jerusalem 91031, Israel Tel: +972 2 655 5361; fax: +972 2 655 5080; e-mail: firstname.lastname@example.org Received 13 August 2008 Revised form accepted 16 September 2008 © 2009 Lippincott Williams & Wilkins, Inc.